In Depth 18 Nov 2024
What is Abcam’s founder, Jonathan Milner, up to?
Since Abcam was acquired in December 2023, its founder, Jonathan Milner has been very active. Delve into his investment strategy.
Drug discovery
- Latest Posts
In Depth 1 Nov 2024
Can AI cure Alzheimer’s disease?
A couple of weeks back, we took a look at how artificial intelligence (AI) has had a transformative impact on cancer research. Today, we take a look at how AI tools help tackle another formidable challenge of modern biotech, Alzheimer’s disease. “Alzheimer’s is an incredibly complex disease with numerous factors at play. You have the […]
In Depth 18 Oct 2024
The AI boom in cancer: Game-changer or just hype?
Is AI just hype or a game-changer? Delve into AI’s contribution to oncology, from diagnostics to drug discovery and personalized treatment.
Best in Biotech 14 Oct 2024
Six biomimicry biotech companies harnessing nature’s wisdom to develop breakthrough drug candidates
Find out more about six biomimicry companies harnessing nature’s wisdom to create drug candidates for the benefit of human health.
How an innovative, data-driven approach is revolutionizing drug discovery for solid tumors
Learn how cancer tissue biobanks and insights into solid tumor heterogeneity are transforming drug discovery and paving the way for innovative treatments.
News and Trends 10 Sep 2024
Long non-coding RNAs: what’s behind the growing “dark genome” buzz?
Recent deals have zoned in on drugs that target long non-coding RNAs and major moves are currently being made on the R&D front.
ADVERTISEMENT
ADVERTISEMENT
Podcast 2 Aug 2024
Rebroadcast: How does AI assist drug discovery?
Listen to our podcast to discover how AI is revolutionizing drug discovery by tackling “undruggable” targets like KRAS.
Podcast 19 Jul 2024
Cutting through the AI hype in drug discovery
There’s certainly hype around AI, but what can it really do in drug discovery? Listen to our conversation with LabGenius to find out.
The untapped power of multivariate analysis for target identification in cancer drug discovery
Discover how multivariate analysis is transforming target identification in cancer drug discovery by moving beyond traditional methods.
Powering up biologics development using mammalian cell lines
Explore how mammalian cell lines drive biopharmaceutical innovation, acting as mini-factories for vital biotherapeutics and vaccines.
Cell avidity-tuning ensures safe CAR-T therapy for solid tumors
Learn more about the potential of cell avidity in designing potent and safe CAR-T treatments for solid tumors.
In Depth 17 Apr 2024
Small but mighty: The role of small-molecule drugs in disease treatment
Find out more about small-molecule drugs, including how they work and what their advantages and disadvantages are.
ADVERTISEMENT
